170 related articles for article (PubMed ID: 34493594)
21. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
22. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
[TBL] [Abstract][Full Text] [Related]
23. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
24. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
26. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
Zhang S; Huang WC; Zhang L; Zhang C; Lowery FJ; Ding Z; Guo H; Wang H; Huang S; Sahin AA; Aldape KD; Steeg PS; Yu D
Cancer Res; 2013 Sep; 73(18):5764-74. PubMed ID: 23913825
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2
Bhan A; Ansari KI; Chen MY; Jandial R
Cancer Res; 2021 Jun; 81(12):3200-3214. PubMed ID: 33941612
[TBL] [Abstract][Full Text] [Related]
28. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
30. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
31. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
32. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
[TBL] [Abstract][Full Text] [Related]
34. EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
Jin Y; Zhang W; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Oncol Rep; 2016 Feb; 35(2):771-8. PubMed ID: 26718028
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
36. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
37. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.
Zhang J; Yin YT; Wu CH; Qiu RL; Jiang WJ; Deng XG; Li ZX
Dis Markers; 2019; 2019():8186091. PubMed ID: 31827645
[TBL] [Abstract][Full Text] [Related]
38. TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.
Irie H; Ito K; Fujioka Y; Oguchi K; Fujioka A; Hashimoto A; Ohsawa H; Tanaka K; Funabashi K; Araki H; Kawai Y; Shimamura T; Wadhwa R; Ohkubo S; Matsuo K
Mol Cancer Ther; 2019 Apr; 18(4):733-742. PubMed ID: 30787176
[TBL] [Abstract][Full Text] [Related]
39. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
[TBL] [Abstract][Full Text] [Related]
40. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]